Clinicians face two choices with the meningococcal B vaccines, Trumemba and Bexsero.
First, should you offer to vaccinate patients?
The CDC does not recommend routine use of either vaccine to immunocompetent individuals, but instead says vaccination should be “optional.”
There are some unknowns to consider:
- How long does protection last?
- Does it affect nasopharyngeal carriage?
- What percentage of meningococcal disease will vaccination prevent? (Neither vaccine covers all the B strains.)
Another concern: is vaccination the best use of healthcare dollars? A complete series costs more than $300.
Do you know how many US cases of meningococcal disease (all strains) were reported in 2015?
Please click on "next" below for answer and discussion.